RU2557654C3 - Терапевтические агенты для снижения уровней паратиреоидного гормона - Google Patents
Терапевтические агенты для снижения уровней паратиреоидного гормонаInfo
- Publication number
- RU2557654C3 RU2557654C3 RU2012107428A RU2012107428A RU2557654C3 RU 2557654 C3 RU2557654 C3 RU 2557654C3 RU 2012107428 A RU2012107428 A RU 2012107428A RU 2012107428 A RU2012107428 A RU 2012107428A RU 2557654 C3 RU2557654 C3 RU 2557654C3
- Authority
- RU
- Russia
- Prior art keywords
- level
- reduce
- therapeutic agents
- paratyroid
- hormone
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 229940088597 hormone Drugs 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22969509P | 2009-07-29 | 2009-07-29 | |
| US61/229,695 | 2009-07-29 | ||
| US25581609P | 2009-10-28 | 2009-10-28 | |
| US61/255,816 | 2009-10-28 | ||
| US31363510P | 2010-03-12 | 2010-03-12 | |
| US61/313,635 | 2010-03-12 | ||
| PCT/US2010/043792 WO2011014707A2 (en) | 2009-07-29 | 2010-07-29 | Therapeutic agents for reducing parathyroid hormone levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2012107428A RU2012107428A (ru) | 2013-09-10 |
| RU2557654C2 RU2557654C2 (ru) | 2015-07-27 |
| RU2557654C3 true RU2557654C3 (ru) | 2017-07-05 |
Family
ID=43527590
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012107428A RU2557654C3 (ru) | 2009-07-29 | 2010-07-29 | Терапевтические агенты для снижения уровней паратиреоидного гормона |
Country Status (29)
| Country | Link |
|---|---|
| US (11) | US8999932B2 (OSRAM) |
| EP (5) | EP3808363B1 (OSRAM) |
| JP (3) | JP5270799B2 (OSRAM) |
| KR (1) | KR101781841B1 (OSRAM) |
| CN (2) | CN107674114B (OSRAM) |
| AU (1) | AU2010278897B2 (OSRAM) |
| BR (1) | BR112012002143B8 (OSRAM) |
| CA (1) | CA2769525C (OSRAM) |
| CY (3) | CY1118388T1 (OSRAM) |
| DK (2) | DK3192520T3 (OSRAM) |
| ES (2) | ES2729051T3 (OSRAM) |
| FR (1) | FR17C1009I2 (OSRAM) |
| HR (2) | HRP20161614T1 (OSRAM) |
| HU (3) | HUE043838T2 (OSRAM) |
| IL (1) | IL217749A (OSRAM) |
| LT (3) | LT3192520T (OSRAM) |
| LU (1) | LUC00008I2 (OSRAM) |
| MX (1) | MX2012001213A (OSRAM) |
| NO (1) | NO2017021I1 (OSRAM) |
| NZ (1) | NZ597922A (OSRAM) |
| PL (2) | PL3192520T3 (OSRAM) |
| PT (2) | PT2459208T (OSRAM) |
| RU (1) | RU2557654C3 (OSRAM) |
| SG (2) | SG10201406921SA (OSRAM) |
| SI (2) | SI3192520T1 (OSRAM) |
| SM (3) | SMT201900307T1 (OSRAM) |
| TW (1) | TWI520744B (OSRAM) |
| WO (1) | WO2011014707A2 (OSRAM) |
| ZA (1) | ZA201200726B (OSRAM) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101552843B1 (ko) | 2006-11-16 | 2015-09-14 | 카이 파마슈티컬즈 | 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드 |
| PT2459208T (pt) | 2009-07-29 | 2017-01-03 | Kai Pharmaceuticals Inc | Agentes terapêuticos para redução dos niveis de hormona paratiroideia |
| KR101493717B1 (ko) | 2010-03-04 | 2015-02-16 | 아지노모토 가부시키가이샤 | 알킬아민 유도체 |
| JP5761173B2 (ja) | 2010-03-04 | 2015-08-12 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| WO2011118843A1 (ja) | 2010-03-24 | 2011-09-29 | 味の素株式会社 | グルタミン酸エステル誘導体又はその塩 |
| JPWO2011126099A1 (ja) | 2010-04-02 | 2013-07-11 | 味の素株式会社 | 糖尿病又は肥満症の予防又は治療剤 |
| SMT201700081T1 (it) * | 2011-06-08 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la regolazione del fosforo sierico |
| HK1202086A1 (en) | 2011-11-10 | 2015-09-18 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
| US20150126457A1 (en) | 2012-04-17 | 2015-05-07 | Brown University | Neuroprotective composition and method of use |
| US20200354428A9 (en) | 2013-06-23 | 2020-11-12 | Wisconsin Alumni Research Foundation | Analogues of parathyroid hormone (1-34) that function as agonists of the parathyroid hormone receptor-1 and display modified activity profiles |
| LT3013318T (lt) * | 2013-06-28 | 2017-09-11 | Amgen Inc. | Stabili amg 416 (velcalcetide) kompozicija |
| SG11201608176VA (en) * | 2014-04-03 | 2016-10-28 | Amgen Inc | Method for preparing amg 416 |
| CN105504012A (zh) * | 2014-09-30 | 2016-04-20 | 深圳翰宇药业股份有限公司 | 一种多肽的制备方法 |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| AU2016238233B2 (en) * | 2015-03-26 | 2019-11-21 | Amgen Inc. | Solution phase method for preparing etelcalcetide |
| US9336841B1 (en) * | 2015-04-16 | 2016-05-10 | Taiwan Semiconductor Manufacturing Co., Ltd. | Pipeline register with data alignment therein |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| CN106928321B (zh) * | 2015-12-31 | 2019-07-26 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| US10105375B2 (en) | 2016-08-30 | 2018-10-23 | Wisconsin Alumni Research Foundation | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism |
| MA50582A (fr) * | 2017-11-07 | 2020-09-16 | Alphacore Pharma Llc | Méthodes de traitement et de protection contre une maladie cardiaque, une maladie cardiovasculaire et des états et des symptômes associés |
| HUE072117T2 (hu) | 2017-12-20 | 2025-10-28 | Ea Pharma Co Ltd | Gyógyszerkészítmény másodlagos hiperparatireoidizmus megelõzésére vagy kezelésére fenntartó dialízis alatt |
| KR101933685B1 (ko) * | 2018-06-29 | 2018-12-28 | 주식회사 에스알바이오텍 | 약물이 코팅된 마이크로 니들 및 이의 제조방법 |
| EP3906059A4 (en) * | 2018-11-02 | 2022-06-22 | Ampersand Biopharmaceuticals, Inc. | MANAGING THE RISK OF CATION OVERLOAD AND ELECTROLYTE BALANCE WITH TOPICALLY APPLIED BUFFER |
| BR112021013002A2 (pt) | 2019-04-03 | 2021-10-13 | Ea Pharma Co., Ltd. | Composição medicinal |
| CN114222578B (zh) * | 2019-12-09 | 2024-06-25 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物及其应用 |
| WO2021226064A1 (en) * | 2020-05-04 | 2021-11-11 | University Of Louisville Research Foundation, Inc. | Artificial intelligence-based systems and methods for dosing of pharmacologic agents |
| WO2022052471A1 (zh) * | 2020-09-10 | 2022-03-17 | 陕西麦科奥特科技有限公司 | 双特异性融合多肽化合物 |
| US11359134B2 (en) | 2020-10-19 | 2022-06-14 | Saudi Arabian Oil Company | Treatment fluids and methods for recovering hydrocarbons from a subterranean formation |
| WO2022257940A1 (zh) * | 2021-06-08 | 2022-12-15 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
| CN117295510A (zh) * | 2021-06-08 | 2023-12-26 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
| EP4593867A2 (en) | 2022-09-30 | 2025-08-06 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| WO2025054169A1 (en) * | 2023-09-05 | 2025-03-13 | Wake Forest University Health Sciences | Compositions and methods for topical treatment |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) * | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| AU9131091A (en) * | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6031003A (en) * | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5814603A (en) * | 1992-06-12 | 1998-09-29 | Affymax Technologies N.V. | Compounds with PTH activity |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| ATE304020T1 (de) | 1996-07-31 | 2005-09-15 | Gen Hospital Corp | Parathyroidhormon-verwandthe peptidanaloge |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) * | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| WO1998033812A1 (en) * | 1997-02-05 | 1998-08-06 | Brigham And Women's Hospital, Inc. | Mast cell protease peptide inhibitors |
| CA2290443A1 (en) | 1997-05-14 | 1998-11-19 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Peptide parathyroid hormone analogs |
| ES2210761T3 (es) * | 1997-05-21 | 2004-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas. |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| US7399489B2 (en) | 1999-01-14 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Exendin analog formulations |
| JP2000336099A (ja) * | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) * | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US20020068342A1 (en) * | 2000-02-09 | 2002-06-06 | Rami Khosravi | Novel nucleic acid and amino acid sequences and novel variants of alternative splicing |
| AU7895601A (en) | 2000-07-18 | 2002-01-30 | Bone Care Int Inc | Stabilized 1alpha-hydroxy vitamin d |
| DE10041126A1 (de) * | 2000-08-22 | 2002-04-04 | Aventis Res & Tech Gmbh & Co | DNA-bindende Peptiddomänen und ein Verfahren zur Bereitstellung solcher Domänen |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) * | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| AU2002226061B2 (en) * | 2001-01-18 | 2007-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta PKC |
| WO2002062396A2 (en) | 2001-02-08 | 2002-08-15 | University Of Medicine And Dentistry Of New Jersey | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) * | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| EP1363934B1 (en) | 2001-02-23 | 2014-10-08 | Polyphor Ltd. | Template-fixed peptidomimetics with antimicrobial activity |
| WO2003013543A1 (en) | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
| WO2003014078A2 (en) * | 2001-08-08 | 2003-02-20 | The Research Foundation Of The State University Of New York | Muc7d1 peptides as antifungal and antibacterial agents |
| US7060023B2 (en) | 2001-09-25 | 2006-06-13 | The Foundry Inc. | Pericardium reinforcing devices and methods of using them |
| US7037897B2 (en) * | 2001-10-31 | 2006-05-02 | Abbott Laboratories | TRI-, TETRA-, and penta-peptides having antiangiogenic activity |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| WO2004039940A2 (en) * | 2002-05-14 | 2004-05-13 | Bristol-Myers Squibb Company | Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof |
| AU2004291277A1 (en) | 2003-11-05 | 2005-06-02 | Intercell Ag | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| US20060052303A1 (en) * | 2004-07-27 | 2006-03-09 | Sampath Kuber T | Use of thyrotropin for regeneration of bone |
| US7265092B2 (en) * | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| DE102005013846A1 (de) | 2005-03-24 | 2006-10-05 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
| KR100687932B1 (ko) * | 2005-08-09 | 2007-02-27 | 삼성전자주식회사 | 영상표시장치 및 영상표시방법 |
| EP1937064A4 (en) * | 2005-08-30 | 2009-09-16 | Acologix Inc | REGULATION OF MINERALS AND SKELETAL METABOLISM |
| KR101552843B1 (ko) | 2006-11-16 | 2015-09-14 | 카이 파마슈티컬즈 | 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드 |
| CN103524623A (zh) | 2007-01-19 | 2014-01-22 | 凯制药公司 | 肽组合物的修饰以提高稳定性和递送效率 |
| JP5697450B2 (ja) * | 2007-10-02 | 2015-04-08 | マリーナ バイオテック，インコーポレイテッド | 核酸の送達のためのリポペプチド |
| WO2009075773A2 (en) | 2007-12-07 | 2009-06-18 | Goldstein Steven A | Identification of toxin ligands |
| US20090318351A1 (en) * | 2008-03-12 | 2009-12-24 | Kevin Grimes | Method of treating acute st-elevation myocardial infarction with a delta pkc antagonist |
| PT2459208T (pt) * | 2009-07-29 | 2017-01-03 | Kai Pharmaceuticals Inc | Agentes terapêuticos para redução dos niveis de hormona paratiroideia |
| SMT201700081T1 (it) * | 2011-06-08 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la regolazione del fosforo sierico |
| HK1202086A1 (en) | 2011-11-10 | 2015-09-18 | Kai Pharmaceuticals, Inc. | Calcimimetics and methods for their use |
-
2010
- 2010-07-29 PT PT108050782T patent/PT2459208T/pt unknown
- 2010-07-29 LT LTEP16190682.1T patent/LT3192520T/lt unknown
- 2010-07-29 ES ES16190682T patent/ES2729051T3/es active Active
- 2010-07-29 CN CN201710873189.9A patent/CN107674114B/zh active Active
- 2010-07-29 HU HUE16190682A patent/HUE043838T2/hu unknown
- 2010-07-29 PT PT16190682T patent/PT3192520T/pt unknown
- 2010-07-29 SM SM20190307T patent/SMT201900307T1/it unknown
- 2010-07-29 NZ NZ597922A patent/NZ597922A/en unknown
- 2010-07-29 ES ES10805078.2T patent/ES2607954T3/es active Active
- 2010-07-29 HU HUE10805078A patent/HUE030960T2/en unknown
- 2010-07-29 US US12/846,724 patent/US8999932B2/en active Active
- 2010-07-29 SM SM20170014T patent/SMT201700014T1/it unknown
- 2010-07-29 SI SI201031894T patent/SI3192520T1/sl unknown
- 2010-07-29 SI SI201031337A patent/SI2459208T1/sl unknown
- 2010-07-29 CA CA2769525A patent/CA2769525C/en active Active
- 2010-07-29 EP EP20209086.6A patent/EP3808363B1/en active Active
- 2010-07-29 PL PL16190682T patent/PL3192520T3/pl unknown
- 2010-07-29 SG SG10201406921SA patent/SG10201406921SA/en unknown
- 2010-07-29 EP EP10805078.2A patent/EP2459208B1/en active Active
- 2010-07-29 TW TW099125105A patent/TWI520744B/zh active
- 2010-07-29 DK DK16190682.1T patent/DK3192520T3/da active
- 2010-07-29 DK DK10805078.2T patent/DK2459208T3/en active
- 2010-07-29 RU RU2012107428A patent/RU2557654C3/ru active
- 2010-07-29 SG SG2012006185A patent/SG178143A1/en unknown
- 2010-07-29 WO PCT/US2010/043792 patent/WO2011014707A2/en not_active Ceased
- 2010-07-29 BR BR112012002143A patent/BR112012002143B8/pt active IP Right Grant
- 2010-07-29 PL PL10805078T patent/PL2459208T3/pl unknown
- 2010-07-29 HR HRP20161614TT patent/HRP20161614T1/hr unknown
- 2010-07-29 KR KR1020127004785A patent/KR101781841B1/ko active Active
- 2010-07-29 SM SM201700014T patent/SMT201700014B/it unknown
- 2010-07-29 AU AU2010278897A patent/AU2010278897B2/en active Active
- 2010-07-29 EP EP16190682.1A patent/EP3192520B1/en active Active
- 2010-07-29 EP EP19159337.5A patent/EP3539555B1/en active Active
- 2010-07-29 JP JP2012523061A patent/JP5270799B2/ja active Active
- 2010-07-29 MX MX2012001213A patent/MX2012001213A/es active IP Right Grant
- 2010-07-29 CN CN201080045024.9A patent/CN102711789B/zh active Active
- 2010-07-29 EP EP22193946.5A patent/EP4154900B1/en active Active
- 2010-07-29 LT LTEP10805078.2T patent/LT2459208T/lt unknown
-
2012
- 2012-01-26 IL IL217749A patent/IL217749A/en active Protection Beyond IP Right Term
- 2012-01-30 ZA ZA2012/00726A patent/ZA201200726B/en unknown
- 2012-02-02 US US13/365,213 patent/US8377880B2/en active Active
-
2013
- 2013-02-18 US US13/769,744 patent/US9278995B2/en active Active
- 2013-05-09 JP JP2013099331A patent/JP5764613B2/ja active Active
-
2014
- 2014-02-10 JP JP2014023488A patent/JP2014094967A/ja active Pending
-
2015
- 2015-03-04 US US14/639,020 patent/US9567370B2/en active Active
-
2016
- 2016-02-08 US US15/018,567 patent/US9701712B2/en active Active
- 2016-12-27 CY CY20161101349T patent/CY1118388T1/el unknown
-
2017
- 2017-01-09 US US15/402,133 patent/US20170114095A1/en not_active Abandoned
- 2017-03-01 HU HUS1700008 patent/HUS1700008I1/hu unknown
- 2017-03-09 LU LU00008C patent/LUC00008I2/fr unknown
- 2017-03-10 LT LTPA2017007C patent/LTC2459208I2/lt unknown
- 2017-03-16 CY CY2017010C patent/CY2017010I2/el unknown
- 2017-03-17 FR FR17C1009C patent/FR17C1009I2/fr active Active
- 2017-05-05 NO NO2017021C patent/NO2017021I1/no unknown
- 2017-06-21 US US15/629,536 patent/US10280198B2/en active Active
-
2019
- 2019-03-11 US US16/298,902 patent/US20190194252A1/en not_active Abandoned
- 2019-05-17 HR HRP20190923TT patent/HRP20190923T1/hr unknown
- 2019-05-31 CY CY20191100579T patent/CY1121922T1/el unknown
-
2020
- 2020-09-02 US US17/010,773 patent/US20200399309A1/en not_active Abandoned
-
2022
- 2022-10-04 US US17/960,060 patent/US20240116983A1/en not_active Abandoned
-
2025
- 2025-01-16 US US19/025,984 patent/US20250163103A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2557654C3 (ru) | Терапевтические агенты для снижения уровней паратиреоидного гормона | |
| PT2493478T (pt) | Composições terapêuticas concentradas de fosfolípidos | |
| BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
| BRPI1011441A2 (pt) | cinta corporal terapeutica | |
| LT2596786T (lt) | Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti | |
| BRPI0916931A2 (pt) | agentes terapêuticos | |
| EP2647707A4 (en) | THERAPEUTICS WITH CYTOTOXICITY INDICATION | |
| EP2398483A4 (en) | Oxyntomodulin Analogs | |
| HRP20170972T1 (hr) | Kombinacijska terapija afukoziliranog cd20-protutijela s bendamustinom | |
| GB0921075D0 (en) | Novel combination of the therapeutic agents | |
| SMT201600219B (it) | Ormone follicolo-stimolante ricombinante umano migliorato | |
| HUE054196T2 (hu) | Terápiás szerek nemkívánatos sejtproliferációhoz kapcsolódó betegségek kezelésére | |
| PL2552484T3 (pl) | Sposoby i preparaty służące do zmniejszenia poziomu hormonu przytarczyc | |
| EP2442821A4 (en) | SAFE ADMINISTRATION OF DESMOPRESSIN | |
| EP2653168A4 (en) | THERAPEUTICS FOR BELT DISPOSAL | |
| HRP20182043T8 (hr) | Upotreba anti-koneksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze | |
| CO6801718A2 (es) | Composición terapéutica para el tratamiento de glioblastoma | |
| HRP20160929T1 (hr) | Terapijski režimi | |
| SMT201600041B (it) | Agenti terapeutici 713 | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| IT1395539B1 (it) | Piede d'appoggio | |
| EP2427183A4 (en) | THERAPEUTIC COMPOUNDS | |
| EP2454248A4 (en) | ANTI FLU RESOURCES | |
| BRPI1013903A2 (pt) | tratamentos terapêuticos utilizando centaquina | |
| EP2496704A4 (en) | THERAPEUTIC COMPOUNDS |